Bioforce Nanosciences Holdings Stock Current Valuation
| BFNH Stock | USD 1.09 0.00 0.00% |
Valuation analysis of BioForce Nanosciences helps investors to measure BioForce Nanosciences' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that BioForce Nanosciences' price fluctuation is abnormally volatile at this time. Calculation of the real value of BioForce Nanosciences is based on 3 months time horizon. Increasing BioForce Nanosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since BioForce Nanosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BioForce Pink Sheet. However, BioForce Nanosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.09 | Real 0.89 | Hype 1.09 | Naive 1.03 |
The intrinsic value of BioForce Nanosciences' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence BioForce Nanosciences' stock price.
Estimating the potential upside or downside of BioForce Nanosciences Holdings helps investors to forecast how BioForce pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BioForce Nanosciences more accurately as focusing exclusively on BioForce Nanosciences' fundamentals will not take into account other important factors: BioForce Nanosciences Holdings Company Current Valuation Analysis
BioForce Nanosciences' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current BioForce Nanosciences Current Valuation | 50.2 M |
Most of BioForce Nanosciences' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioForce Nanosciences Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, BioForce Nanosciences Holdings has a Current Valuation of 50.2 M. This is 99.74% lower than that of the Consumer Defensive sector and 99.49% lower than that of the Packaged Foods industry. The current valuation for all United States stocks is 99.7% higher than that of the company.
BioForce Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioForce Nanosciences' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of BioForce Nanosciences could also be used in its relative valuation, which is a method of valuing BioForce Nanosciences by comparing valuation metrics of similar companies.BioForce Nanosciences is currently under evaluation in current valuation category among its peers.
BioForce Fundamentals
| Return On Asset | -21.84 | |||
| Current Valuation | 50.2 M | |||
| Shares Outstanding | 29.27 M | |||
| Shares Owned By Insiders | 82.29 % | |||
| Price To Earning | (1.52) X | |||
| Price To Book | 866.24 X | |||
| Price To Sales | 3,841 X | |||
| Gross Profit | 4.36 K | |||
| EBITDA | (501.95 K) | |||
| Net Income | (501.95 K) | |||
| Cash And Equivalents | 9.23 K | |||
| Total Debt | 156.87 K | |||
| Debt To Equity | 4.61 % | |||
| Current Ratio | 0.01 X | |||
| Book Value Per Share | (0.04) X | |||
| Cash Flow From Operations | (77.77 K) | |||
| Earnings Per Share | (0.02) X | |||
| Target Price | 0.25 | |||
| Beta | -1.93 | |||
| Market Capitalization | 72.74 M | |||
| Total Asset | 11.14 K | |||
| Retained Earnings | (21 K) | |||
| Working Capital | 14 K | |||
| Current Asset | 15 K | |||
| Current Liabilities | 1 K | |||
| Net Asset | 11.14 K |
About BioForce Nanosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioForce Nanosciences Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioForce Nanosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioForce Nanosciences Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in BioForce Pink Sheet
BioForce Nanosciences financial ratios help investors to determine whether BioForce Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioForce with respect to the benefits of owning BioForce Nanosciences security.